Atypical Hemolytic Uremic Syndrome Clinical Trials

7 recruiting

Atypical Hemolytic Uremic Syndrome Trials at a Glance

7 actively recruiting trials for atypical hemolytic uremic syndrome are listed on ClinicalTrialsFinder across 6 cities in 12 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Ranica, Beijing, and Ankara. Lead sponsors running atypical hemolytic uremic syndrome studies include Mario Negri Institute for Pharmacological Research, Novartis Pharmaceuticals, and Alexion Pharmaceuticals, Inc..

Browse atypical hemolytic uremic syndrome trials by phase

Treatments under study

About Atypical Hemolytic Uremic Syndrome Clinical Trials

Looking for clinical trials for Atypical Hemolytic Uremic Syndrome? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atypical Hemolytic Uremic Syndrome trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atypical Hemolytic Uremic Syndrome clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 3

Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals50 enrolled31 locationsNCT05935215
Recruiting
Phase 4

Post-Marketing Clinical Study of Ravulizumab in Participants With Clinical aHUS

Atypical Hemolytic Uremic SyndromeaHUS
Alexion Pharmaceuticals, Inc.20 enrolled12 locationsNCT07308574
Recruiting

The Burden of Atypical Hemolytic Uremic Syndrome and The Clinical Characteristics of Patients in Egyptian Hospitals A Multicenter, Observational, Retrospective Cohort Study in Egypt

Atypical Hemolytic Uremic Syndrome
AstraZeneca200 enrolled8 locationsNCT07218536
Recruiting
Not Applicable

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

HealthyAtypical Hemolytic Uremic SyndromeMembranoproliferative Glomerulonephritis+1 more
Mario Negri Institute for Pharmacological Research105 enrolled1 locationNCT05996731
Recruiting
Not Applicable

Functional Implications of Rare Gene Mutations in aHUS Open the Door to Personalized Therapy

Atypical Hemolytic Uremic Syndrome
Mario Negri Institute for Pharmacological Research112 enrolled1 locationNCT05805202
Recruiting
Phase 3

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS

Atypical Hemolytic Uremic Syndrome
Novartis Pharmaceuticals125 enrolled6 locationsNCT05795140
Recruiting

National Registry of Rare Kidney Diseases

Denys-Drash SyndromeTuberous SclerosisAutosomal Recessive Polycystic Kidney Disease+81 more
UK Kidney Association35,000 enrolled1 locationNCT06065852